MedTrace Logo

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

NCT00292552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2747

Last updated 2017-03-23

No results posted yet for this study

Summary

This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

OTHER

Novel endpoint determination

Novel endpoint determination

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Denmark
  • Netherlands
  • New Zealand
  • Norway
  • Slovenia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292552 on ClinicalTrials.gov